- Emphysema and chronic bronchitis patients to benefit from rapid, long-lasting symptom control with twice-daily dosing of first nebulized
formoterol fumarate -
NAPA, Calif., Oct. 8 /PRNewswire-FirstCall/ -- Dey, L.P., a subsidiary of Mylan Inc. (NYSE: MYL), today announced the launch of Perforomist(TM) (formoterol fumarate) Inhalation Solution, which will be available nationwide through retail pharmacies, hospitals, long-term care facilities, and home healthcare companies. Perforomist(TM) Inhalation Solution is indicated for long-term, twice-daily maintenance treatment of bronchoconstriction for emphysema and chronic bronchitis, also known as Chronic Obstructive Pulmonary Disease (COPD).
The formoterol molecule is a rapid and long-acting beta2-agonist (LABA) that has been previously available in the U.S. in a dry powder formulation and has twenty years of worldwide experience. Perforomist(TM) Inhalation Solution is the first and only FDA-approved nebulized form of this molecule. Nebulizers convert liquid medication into a mist that patients inhale through a mouthpiece or face mask.
"In treating patients with moderate to advanced COPD, I have found
LABAs to be very effective, and in particular I think formoterol provides
excellent long-term symptom control," said Donald P. Tashkin, MD, FACP,
FCCP, Professor of Medicine, David Geffen School of Medicine at the
University of California at Los Angeles. "Since patients have difficulty
adhering to complicated medication regimens, it's very helpful that
Perforomist(TM) Inhalation Solution offers a twice-daily nebulized version
of formoterol. I consider nebulization to be an especially effective way to
deliver medication into
|SOURCE Dey, L.P.|
Copyright©2007 PR Newswire.
All rights reserved